These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 6483638)

  • 1. Dose dependency for absorption and elimination rates of theophylline. Implications for studies of bioavailability.
    Milavetz G; Weinberger M; Vaughan L
    Pharmacotherapy; 1984; 4(4):216-20. PubMed ID: 6483638
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A clinical and pharmacokinetic basis for the selection and use of slow release theophylline products.
    Hendeles L; Iafrate RP; Weinberger M
    Clin Pharmacokinet; 1984; 9(2):95-135. PubMed ID: 6370542
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relationship between rate and extent of absorption of oral theophylline from Uniphyl brand of slow-release theophylline and resulting serum concentrations during multiple dosing.
    Milavetz G; Vaughan LM; Weinberger MM; Harris JB; Mullenix TA
    J Allergy Clin Immunol; 1987 Nov; 80(5):723-9. PubMed ID: 3680816
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The relation of product formulation to absorption of oral theophylline.
    Weinberger M; Hendeles L; Bighley L
    N Engl J Med; 1978 Oct; 299(16):852-7. PubMed ID: 692577
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics and relative bioavailability of oral theophylline capsules.
    Lesko LJ; Canada AT; Eastwood G; Walker D; Brousseau DR
    J Pharm Sci; 1979 Nov; 68(11):1392-4. PubMed ID: 583162
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Theophylline QID, TID, BID and now QD? A report on 24-hour dosing with slow-release theophylline formulations with emphasis on analyses of data used to obtain Food and Drug Administration approval for Theo-24.
    Weinberger MM
    Pharmacotherapy; 1984; 4(4):181-98. PubMed ID: 6483637
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Absorption characteristics of once-a-day slow-release theophylline preparation in children with asthma.
    Pedersen S; Steffensen G
    J Pediatr; 1987 Jun; 110(6):953-9. PubMed ID: 3585612
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Theophylline product and dosing interval selection for chronic asthma.
    Hendeles L; Weinberger M
    J Allergy Clin Immunol; 1985 Aug; 76(2 Pt 2):285-91. PubMed ID: 4019956
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bioavailability of Theodel, a new theophylline tablet, in humans.
    Rovei V; Strolin Benedetti M; Donath A; Grenot C; Chanoine F
    Int J Clin Pharmacol Ther Toxicol; 1983 Aug; 21(8):425-30. PubMed ID: 6629546
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of aminophylline and theophylline sustained-release formulations by their bioavailability and steady-state serum levels.
    Steinijans VW; Zech K; Fischer R
    Int J Clin Pharmacol Ther Toxicol; 1983 Dec; 21(12):624-30. PubMed ID: 6668100
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetic properties of a new sustained-release theophylline preparation.
    Dahlqvist R; Billing B
    Int J Clin Pharmacol Ther Toxicol; 1983 Feb; 21(2):69-72. PubMed ID: 6840927
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bioavailability of theophylline from a sustained-release aminophylline formulation (Euphyllin retard tablets)--plasma levels after single and multiple oral doses.
    Schuppan D; Molz KH; Staib AH; Rietbrock N
    Int J Clin Pharmacol Ther Toxicol; 1981 May; 19(5):223-7. PubMed ID: 7251238
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Theophylline bioavailability: a comparison of the oral absorption of a theophylline elixir and two combination theophylline tablets to intravenous aminophylline.
    Fixley M; Shen DD; Azarnoff DL
    Am Rev Respir Dis; 1977 Jun; 115(6):955-62. PubMed ID: 262107
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Theophylline bioavailability following chronic dosing of an elixir and two solid dosage forms.
    Shen DD; Fixley M; Azarnoff DL
    J Pharm Sci; 1978 Jul; 67(7):916-9. PubMed ID: 660507
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bioavailability of sustained-release theophylline formulations.
    Bonora Regazzi M; Rondanelli R; Vidale E; Cristiani D
    Int J Clin Pharmacol Ther Toxicol; 1983 May; 21(5):245-51. PubMed ID: 6862729
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relationship of formulation and dosing interval to fluctuation of serum theophylline concentration in children with chronic asthma.
    Weinberger M; Hendeles L; Wong L
    J Pediatr; 1981 Jul; 99(1):145-52. PubMed ID: 7252652
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dissolution and bioavailability studies of whole and halved sustained-release theophylline tablets.
    Simons KJ; Frith EM; Simons FE
    J Pharm Sci; 1982 May; 71(5):505-11. PubMed ID: 7097493
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Absolute bioavailability of oral theophylline.
    Hendeles L; Weinberger M; Bighley L
    Am J Hosp Pharm; 1977 May; 34(5):525-7. PubMed ID: 868891
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Food-induced "dose-dumping" from a once-a-day theophylline product as a cause of theophylline toxicity.
    Hendeles L; Weinberger M; Milavetz G; Hill M; Vaughan L
    Chest; 1985 Jun; 87(6):758-65. PubMed ID: 3996063
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Food induced changes in theophylline absorption from a once-a-day theophylline product.
    Steffensen G; Pedersen S
    Br J Clin Pharmacol; 1986 Nov; 22(5):571-7. PubMed ID: 3790404
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.